Newsmeme!
Discover News you didn't know existed
"DNA technology" is set to change the way some semen companies select bulls and is claimed to be the biggest development since frozen semen.
Title: Chromosome Linked to Diabetics' Heart Risks Category: Health News Created: 11/26/2008 2:00:00 AM Last Editorial Review: 11/26/2008
Genetic variation identifies those with poor glucose control likely to have artery disease.
Valeant Pharmaceuticals, a multinational specialty pharmaceutical company, has reported promising results at end of treatment, week 48 analysis point in the Phase IIb clinical trial for its antiviral compound, taribavirin, a prodrug of ribavirin in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon.
Patients with type 2 diabetes who have poor glycemic control and a certain genetic variation have an increased risk of coronary artery disease, according to a study in the November 26 issue of JAMA, the Journal of the American Medical Association.
TUESDAY, Nov. 25 (HealthDay News) -- Adding to earlier research, a new study has identified a genetic variation that increases the risk of coronary artery disease (CAD) in type 2 diabetes patients with poor sugar glucose (glycemic) control.
( JAMA and Archives Journals ) Patients with type 2 diabetes who have poor glycemic control and a certain genetic variation have an increased risk of coronary artery disease, according to a study in the Nov. 26 issue of JAMA.
Patients with type 2 diabetes who have poor glycemic control and a certain genetic variation have an increased risk of coronary artery disease, according to a study in the November 26 issue of JAMA.
People driving past River Falls-based BioDiagnostics Inc. may notice cars parked all along the street in front of its building at 507 Highland Drive in Whitetail Ridge Corporate Park.
Schering-Plough Corporation (NYSE: SGP) provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |